Misonix, Inc’s (NASDAQ: MSON) CEO Stavros Vizirgianakis took time to update Wall Street Analyzer’s investment audience about the company’s recent developments. During the interview he discussed MSON’s Q3 results, which produced record revenues, and also outlined their partnership with Weigao in China. Mr. Vizirgianakis also provided an overview of Misonix Inc’s key products, SonicOne and BoneScalpel, and addressed how they position them in the wound care and spine surgery sectors. He also went over MSON’s goal of transitioning most of their business to the consumables space, and how that will make their revenues even more stable and predictable.
Misonix, Inc. (NASDAQ: MSON) specializes in the development and commercialization of ultrasonic surgical devices for neurosurgical, spinal, advanced wound care, and general surgery procedures. Their portfolio of products are all based upon the unique properties of ultrasound and its ability to differentiate hard and soft tissue for different clinical requirements. Misonix, Inc. operates in over 45 countries and is a recognized leader in advanced surgical tools offering unprecedented safety, speed, and precision.
Joe Dwyer Misonix, Inc.
Robert Blum, Joe Dorame, Joe Diaz
Lytham Partners, LLC